Mackenzie Financial Corp Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)

Mackenzie Financial Corp lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 84.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 585,766 shares of the biopharmaceutical company's stock after purchasing an additional 267,843 shares during the quarter. Mackenzie Financial Corp's holdings in Bristol-Myers Squibb were worth $33,131,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $25,000. Fairway Wealth LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Transce3nd LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA bought a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Finally, Tacita Capital Inc bought a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $39,000. 76.41% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BMY shares. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Stock Up 1.8%

Shares of BMY traded up $0.83 on Thursday, reaching $47.80. The company's stock had a trading volume of 10,485,969 shares, compared to its average volume of 13,129,818. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock has a market capitalization of $97.27 billion, a PE ratio of -10.81, a PEG ratio of 2.07 and a beta of 0.39. The firm has a fifty day moving average of $50.97 and a 200-day moving average of $55.54.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the business posted ($4.40) EPS. The firm's revenue was down 5.6% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.19%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.